NO974766L - Fremgangsmåte for behandling av dysfunksjon - Google Patents

Fremgangsmåte for behandling av dysfunksjon

Info

Publication number
NO974766L
NO974766L NO974766A NO974766A NO974766L NO 974766 L NO974766 L NO 974766L NO 974766 A NO974766 A NO 974766A NO 974766 A NO974766 A NO 974766A NO 974766 L NO974766 L NO 974766L
Authority
NO
Norway
Prior art keywords
dysfunction
procedure
treatment
methyl
benzodiazepine
Prior art date
Application number
NO974766A
Other languages
English (en)
Other versions
NO318553B1 (no
NO974766D0 (no
Inventor
Jr Charles M Beasley
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002219902A priority Critical patent/CA2219902A1/en
Priority claimed from CA002219902A external-priority patent/CA2219902A1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to NO19974766A priority patent/NO318553B1/no
Publication of NO974766D0 publication Critical patent/NO974766D0/no
Publication of NO974766L publication Critical patent/NO974766L/no
Publication of NO318553B1 publication Critical patent/NO318553B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Processing Of Meat And Fish (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Light Receiving Elements (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19974766A 1995-05-30 1997-10-15 Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon. NO318553B1 (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002219902A CA2219902A1 (en) 1995-05-30 1995-05-30 Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine for treating cognitive dysfunction
NO19974766A NO318553B1 (no) 1995-05-30 1997-10-15 Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon.

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002219902A CA2219902A1 (en) 1995-05-30 1995-05-30 Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno¬2,3b|¬1,5|benzodiazepine for treating cognitive dysfunction
PCT/US1995/006859 WO1996038151A1 (en) 1995-05-30 1995-05-30 Method for treating cognitive dysfunction
NO19974766A NO318553B1 (no) 1995-05-30 1997-10-15 Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon.

Publications (3)

Publication Number Publication Date
NO974766D0 NO974766D0 (no) 1997-10-15
NO974766L true NO974766L (no) 1997-12-09
NO318553B1 NO318553B1 (no) 2005-04-11

Family

ID=25679786

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974766A NO318553B1 (no) 1995-05-30 1997-10-15 Anvendelse av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno[2,3-b][1,5]benzodiazepin for behandling av en kognitiv dysfunksjon.

Country Status (17)

Country Link
EP (1) EP0828494B1 (no)
JP (1) JPH11506096A (no)
AT (1) ATE220550T1 (no)
AU (1) AU707858B2 (no)
CZ (1) CZ292565B6 (no)
DE (1) DE69527442T2 (no)
DK (1) DK0828494T3 (no)
ES (1) ES2180643T3 (no)
FI (1) FI973987A (no)
HK (1) HK1009393A1 (no)
HU (1) HUT77907A (no)
MX (1) MX9707936A (no)
NO (1) NO318553B1 (no)
NZ (1) NZ288037A (no)
PL (1) PL189714B1 (no)
PT (1) PT828494E (no)
WO (1) WO1996038151A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
WO2006073886A1 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Olanzapine pamoate dihydrate
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270464A (en) * 1989-03-14 1993-12-14 Janssen Pharmaceutica N.V. Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP0828494A4 (en) 1999-11-24
DK0828494T3 (da) 2002-09-02
DE69527442T2 (de) 2003-02-20
HK1009393A1 (en) 1999-06-04
AU707858B2 (en) 1999-07-22
ATE220550T1 (de) 2002-08-15
PT828494E (pt) 2002-10-31
CZ324397A3 (cs) 1998-08-12
CZ292565B6 (cs) 2003-10-15
EP0828494B1 (en) 2002-07-17
HUT77907A (hu) 1998-10-28
PL189714B1 (pl) 2005-09-30
MX9707936A (es) 1997-12-31
PL323785A1 (en) 1998-04-27
FI973987A0 (fi) 1997-10-17
NO318553B1 (no) 2005-04-11
WO1996038151A1 (en) 1996-12-05
JPH11506096A (ja) 1999-06-02
NO974766D0 (no) 1997-10-15
AU2693695A (en) 1996-12-18
DE69527442D1 (de) 2002-08-22
NZ288037A (en) 1999-09-29
FI973987A (fi) 1997-10-17
ES2180643T3 (es) 2003-02-16
EP0828494A1 (en) 1998-03-18

Similar Documents

Publication Publication Date Title
MY114701A (en) Process and crystal forms of 2-methyl-thieno- benzodiazepine
IL113912A (en) Use of 2-methyl-10-(4-methyl-1- piperazinyl)-4h-thieno-[2,3-b] [1,5] benzodiazepine for the treatment of functional bowel disorders
NO178766C (no) Analogifremgangsmåte for fremstilling av benzodiazepin og mellomprodukter derav
NO961483D0 (no) Fremgangsmåte for behandling av oljeholdig formasjon
ZA963098B (en) Method for treating dyskinesias.
NZ510208A (en) Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) pamoate salt
EP1181935A3 (en) Agent for treating mental disorders associated with cerebrovascular disorders
NO974766D0 (no) Fremgangsmåte for behandling av dysfunksjon
ZA971566B (en) Method of treating leather with pmphoteric polymers.
NO982911L (no) FremgangsmÕte for behandling av depresjon
TW429149B (en) Pharmaceutical composition for treating conditions resulting from the cessation and withdrawal from the use of nicotine
NZ332037A (en) Olanzapine for treating migraine pain
EP0911028A3 (en) Method for treating sexual dysfunction
DK0831835T3 (da) Behandling af anorexia
IL128028A0 (en) Treatment of psychotic disorders
NZ324615A (en) Method for treating autism using olanzapine
AU2874497A (en) Balanites aegyptiaca method of treatment
HUP9902882A2 (hu) Olanzapin alkalmazása álmatlanság kezelésére szolgáló gyógyszerkészítmények előállítására
NZ331846A (en) Method for preparing a medicament using olanzapine for treating insomnia
ZA963472B (en) Method of treatment.
ZA966936B (en) Process for the treatment of water.
ZA966815B (en) Method of treating water.
AU5715296A (en) Method of treating disorders associated with cholinergic hyp ofunctionality